Applying Fusion Protein Technology to E. coli - Protein fusions are a leading option to produce difficult-to-express proteins, especially in Escherichia coli. - BioPharm International

ADVERTISEMENT

Applying Fusion Protein Technology to E. coli
Protein fusions are a leading option to produce difficult-to-express proteins, especially in Escherichia coli.


BioPharm International


6. Di Guan C, Li P, Riggs PD, Inouye H. Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose-binding protein. Gene. 1988; 67:21–30.

7. Davis GD, Elisee C, Newham DM, Harrison RG. New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol. Bioeng. 1999; 65:382–388.

8. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, McCoy JM. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology. 1993; 11:187–193.

9. Gentz R, Certa U, Takacs B, Matile H, Döbeli H, Pink R, et al. Major surface antigen p190 of Plasmodium falciparum: Detection of common epitopes present in a variety of plasmodia isolates. EMBO J. 1988; 7:225–230.

10. Hochuli E, Bannwarth W, Döbeli H, Gentz R, Stüber D. Genetic approach to facilitate purifaction of recombinant proteins with a novel metal chelate adsorbent. Biotechnol. 1988; 6:1321–1325.

11. Smith MC, Furman TC, Ingolia TD, Pidgeon C. Chelating peptide-immobilized metal ion affinity chromatography. A new concept in affinity chromatography for recombinant proteins. J. Biol. Chem. 1988; 263:7211–7215.

12. Malakhov MP, Mattern MR, Malakhova OA, Drinker M, Weeks SD, Butt TR. SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. J. Struct. Funct. Genomics. 2004; 5:75–86.

13. Zuo X, Li S, Hall J, Mattern MR, Tran H, Shoo J, et al. Enhanced expression and purification of membrane proteins by SUMO fusion in E. coli. J. Struct. Funct. Genomics. 2005; 6:103–111.

14. Zuo X, Mattern MR, Tan R, Li S, Hall J, Sterner DE, et al. Expression and purification of SARS Coronavirus proteins using SUMO fusions. Protein Express Purif. 2005; 42:100–110.

15. Butt TR, Edavettal SC, Hall JP, Mattern MR. SUMO fusion technology for difficult-to-express proteins. Protein Express Purif. 2005; 43:1–9.

16. Marblestone JG, Edavettal SC, Lim Y, Lim P, Zuo X, Butt TR. Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO. Protein Sci. 2006; 15:182–189.

17. Hammarstrom M, Hellgren N, van Den Berg S, Berglund H, Hard T. Rapid screening for improved solubility of small human proteins produced as fusion proteins in Escherichia coli. Protein Sci. 2002; 11(2):313–321.

18. Braun P, Hu Y, Shen B, Halleck A, Koundinya M, Harlow E, LaBaer J. Proteome-scale purification of human proteins from bacteria. Proc. Natl. Acad. Sci. 2002; 99(5):2654–2659.

19. Shih YP, Kung WM, Chen JC, Yeh CH, Wang AH, Wang TF. High-throughput screening of soluble recombinant proteins. Protein Sci. 2002; 11(7):1714–1719.

20. Dyson MR, Shadbolt SP, Vincent KJ, Perera RL, McCafferty J. Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression. BMC Biotechnol. 2004; 4:32.

21. De Marco V, Stier G, Blandin S, de Marco A. The solubility and stability of recombinant proteins are increased by their fusion to NusA. Biochem. Biophys. Res. Commun. 2004; 322:766–771.

22. Sharma SK, Evans DB, Vosters AF, McQuade TJ, Tarpley WG. Metal affinity chromatography of recombinant HIV-1 reverse transcriptase containing a human renin cleavable metal binding domain. Biotechnol. Appl. Biochem. 1991; 14:69–81.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International,
Click here